{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:28:32Z","timestamp":1791217712424,"version":"4.1.0"},"reference-count":62,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,3,19]],"date-time":"2002-03-19T00:00:00Z","timestamp":1016496000000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p>\n                    <jats:bold>Summary:<\/jats:bold>\n                    <jats:bold>\u2002Background:<\/jats:bold>\n                    New continuous infusion antiepileptic drugs (cIV\u2010AEDs) offer alternatives to pentobarbital for the treatment of refractory status epilepticus (RSE). However, no prospective randomized studies have evaluated the treatment of RSE. This systematic review compares the efficacy of midazolam (MDL), propofol (PRO), and pentobarbital (PTB) for terminating seizures and improving outcome in RSE patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We performed a literature search of studies describing the use of MDL, PRO, or PTB for the treatment of RSE published between January 1970 and September 2001, by using MEDLINE, OVID, and manually searched bibliographies. We included peer\u2010reviewed studies of adult patients with SE refractory to at least two standard AEDs. Main outcome measures were the frequency of immediate treatment failure (clinical or electrographic seizures occurring 1 to 6 h after starting cIV\u2010AED therapy) and mortality according to choice of agent and titration goal (cIV\u2010AED titration to \u201cseizure suppression\u201d versus \u201cEEG background suppression\u201d).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Twenty\u2010eight studies describing a total of 193 patients fulfilled our selection criteria: MDL (n = 54), PRO (n = 33), and PTB (n = 106). Forty\u2010eight percent of patients died, and mortality was not significantly associated with the choice of agent or titration goal. PTB was usually titrated to EEG background suppression by using intermittent EEG monitoring, whereas MDL and PRO were more often titrated to seizure suppression with continuous EEG monitoring. Compared with treatment with MDL or PRO, PTB treatment was associated with a lower frequency of short\u2010term treatment failure (8 vs. 23%; p &lt; 0.01), breakthrough seizures (12 vs. 42%; p &lt; 0.001), and changes to a different cIV\u2010AED (3 vs. 21%; p &lt; 0.001), and a higher frequency of hypotension (systolic blood pressure &lt;100 mm Hg; 77 vs. 34%; p &lt; 0.001). Compared with seizure suppression (n = 59), titration of treatment to EEG background suppression (n = 87) was associated with a lower frequency of breakthrough seizures (4 vs. 53%; p &lt; 0.001) and a higher frequency of hypotension (76 vs. 29%; p &lt; 0.001).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Despite the inherent limitations of a systematic review, our results suggest that treatment with PTB, or any cIV\u2010AED infusion to attain EEG background suppression, may be more effective than other strategies for treating RSE. However, these interventions also were associated with an increased frequency of hypotension, and no effect on mortality was seen. A prospective randomized trial comparing different agents and titration goals for RSE with obligatory continuous EEG monitoring is needed.\n                  <\/jats:p>","DOI":"10.1046\/j.1528-1157.2002.28501.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T15:00:23Z","timestamp":1047394823000},"page":"146-153","source":"Crossref","is-referenced-by-count":511,"title":["Treatment of Refractory Status Epilepticus with Pentobarbital, Propofol, or Midazolam: A Systematic Review"],"prefix":"10.1111","volume":"43","author":[{"given":"Jan","family":"Claassen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence\u2003J.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald\u2003G.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan\u2003A.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,3,19]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199307000-00004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391202"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.2.205"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.895"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01269.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00039.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.6.1036"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80106-9"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199804023381407"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17367"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1995.tb15095.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.1983.03330350028021","article-title":"Double\u2010blind study of lorazepam and diazepam in status epilepticus.","volume":"249","author":"Leppik IE","year":"1983","journal-title":"JAMA"},{"key":"e_1_2_6_14_2","first-page":"307","article-title":"Potentiation of GABA by midazolam and its therapeutic effect against status epilepticus.","volume":"37","author":"Kaneko S","year":"1983","journal-title":"Folia Psychiatry Neurol Jpn"},{"key":"e_1_2_6_15_2","first-page":"261","article-title":"Midazolam treatment of acute and refractory status epilepticus.","volume":"22","author":"Fountain NB","year":"1999","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199403000-00022"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.14-12-07747.1994"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2000.00649.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448020-00003"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1177\/106002809603001217","article-title":"Midazolam in refractory status epilepticus.","volume":"30","author":"Denzel D","year":"1996","journal-title":"Ann Pharmacother"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198917050-00002"},{"key":"e_1_2_6_22_2","first-page":"267","article-title":"Assay for cyclo\u2010, seco\u2010 and pentobarbital by multiple ion detection: kinetics after a single dose.","volume":"20","author":"Steudel H","year":"1982","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb05908.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.3.500"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1990.tb05361.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.3.395"},{"key":"e_1_2_6_27_2","first-page":"85","article-title":"Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus.","volume":"270","author":"Working Group on Status Epilepticus Treatment of Convulsive Status Epilepticus","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-198510000-00009"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91281-0"},{"key":"e_1_2_6_30_2","first-page":"322","article-title":"Continuous infusion of midazolam hydrochloride to control status epilepticus.","volume":"7","author":"Crisp CB","year":"1988","journal-title":"Clin Pharm"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199204000-00009"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199310000-00013"},{"key":"e_1_2_6_33_2","first-page":"109","article-title":"Treatment of status epilepticus with midazolam: report of four cases.","volume":"9","author":"Galdames Poblete D","year":"1994","journal-title":"Neurologia"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.10.1837"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199502000-00028"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.6.1366"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.27500.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1988.tb06658.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1990.tb14884.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1990.tb14664.x"},{"key":"e_1_2_6_41_2","first-page":"176","article-title":"Propofol in the treatment of convulsive status epilepticus: a report of four cases.","volume":"61","author":"Campostrini R","year":"1991","journal-title":"Riv Neurol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01705733"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(95)80099-9"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.1995.tb03177.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb01513.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100022769"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05327.x"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6974(94)90114-7"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00775.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90646-0"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03540160054033"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370806"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.4.844"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-5-199703010-00008"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb00073.x"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00774.x"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90415-5"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.3_Part_1.483"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02908.x"},{"key":"e_1_2_6_60_2","first-page":"293","volume-title":"Status epilepticus: its clinical features and treatment in children and adults","author":"Shorvon S","year":"1999"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01177.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17367"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550030-00008"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1528-1157.2002.28501.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1528-1157.2002.28501.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:55:59Z","timestamp":1695855359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1528-1157.2002.28501.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1046\/j.1528-1157.2002.28501.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1528-1157.2002.28501.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}